Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

By Padmanabhan Ananthan (Reuters) -In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal in a late-stage trial for patients aged ...

Long term Global Blood Therapeutics, Inc. (NASDAQ:GBT) shareholders know that all too well, since the share price is down considerably over three years. Sadly for them, the share price is down 58% ...

Global Blood Therapeutics novel sickle cell disease drug, Oxbryta, continues to outperform revenue expectations early in its launch despite the "pandemic era". It is evident in both the data and ...

In response to receiving Breakthrough Therapy Designation from the FDA on the company's lead compound, shares of Global Blood Therapeutics (NASDAQ: GBT), a clinical-stage biotech focused on blood ...

Global Blood Therapeutics provided investors with a preliminary update from its phase 3 HOPE study. This 154-patient trial is testing its drug Voxelotor as a treatment for kids with sickle cell ...

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders ...

Global blood cancer therapeutics market size will grow by USD 12.63 billion during 2019-2023, at a CAGR of over 8%. There is an increase in advances in the research of regenerative therapies due ...

What happenedShares of hematology biotech Global Blood Therapeutics (NASDAQ: GBT) are up 16.5% as of 10:30 a.m. EDT after the company posted upbeat second-quarter 2021 earnings. Sales of its ...

Global Blood, based in South San Francisco, Calif., had expected to price its offering at $16 to $18 per share. Its stock is listed on the Nasdaq Global Market under the symbol “GBT.” Policies ...